`Atty. Docket No.: GWLG-017US-CIP
`Response to Final Off1ce Action
`
`“The background art does not
`
`teach or
`
`suggest markers
`
`for
`
`endometriosis that are sufficiently sensitive and/0r accurate, alone or in
`
`combination.”
`
`(Cohen el al., [0014], emphasis added.)
`
`Thus, Applicant respectfully submits that Cohen el al., in View of Telimaa el 61]., fails to
`
`teach the use of glycodelin as an effective biomarker for diagnosis of endometriosis. Furthermore,
`
`Cohen el a]. does not teach the use of glycodelin in combination with one or more of BDNF, ZAG
`
`and CA125 to diagnose endometriosis as claimed.
`
`In fact, Cohen el al.
`
`teaches away from
`
`combining glycodelin with these other biomarkers.
`
`The claimed method of diagnosing and treating endometriosis in a mammal including the
`
`
`step of detecting the circulating levels of glycodelin and one or more of BDNF ZAG and CA125
`
`advantageously exhibits a high level of specificity (e. g, greater than 70%) with respect to the
`
`diagnosis of endometriosis in comparison to the low sensitivity described by Cohen el al.
`
`Thus, claim 1 and the claims dependent thereon are believed to be both novel and
`
`nonobvious in View of Cohen el al, and thus in compliance with 35 USC §102 and §103.
`
`With regard to claims 8-12, the Examiner alleges that in View of art cited with respect to
`
`the biomarkers (Cohen el al., Browne el al., Ward el al. and Signorile el 61].), and the Ahern
`
`reference, it would have been obvious for one of skill in the art to compile the components of the
`
`claimed kit. Applicant disagrees.
`
`Amended claim 8 defines a kit comprising a glycodelin-specific reactant, and one or more
`
`of a ZAG-specific reactant, a BDNF-specific reactant and a CA-lZS-specific reactant for use in a
`
`method to diagnose endometriosis in a mammal.
`
`10
`
`